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INTRODUCTION
Gout is an inflammatory arthritis that is associated with
hyperuricemia, and also is widely known to be associated
with obesity, dyslipidemia, hyperglycemia and hypertension.
Such metabolic abnormalities have recently been increasingly
recognized as not being separate illnesses, but rather they
are a clustered syndrome that has been termed the ‘‘metabolic
syndrome’’ (1). Metabolic syndrome has gained significant
attention through the ATP (Adult Treatment Panel) III guide-
lines and it is considered to be an independent risk factor for
cardiovascular diseases that is comparable to smoking.
It has been suggested that hyperuricemia and possibly gout
are associated with insulin resistance or with metabolic syn-
drome (2-6), but no prevalence study has been done using
the ATP III classification criteria. We recently conducted a
single-center study (7) concerning this issue, and found the
prevalence of metabolic syndrome with gout to be signifi-
cantly higher than that in the general population (42.2% vs.
6.8%, gout vs. historical control, ATP III criteria used). This
study is an expansion of our previous study with the purpose
to discover the prevalence of the metabolic syndrome in pati-
ents with gout and compare it with the historical controls.
We also determined the factors associated with metabolic
syndrome.
MATERIALS AND METHODS 
This was a case-historical control study undertaken in four
institutes; Korea University Anam and Guro Hospital, Daegu
Catholic University Medical Center and Dong-A University
Hospital. A total of 168 patients with gout were recruited
and they were checked for the presence of metabolic syndrome
according to the ATP III criteria (1). The presence of metabolic
syndrome was defined as those patients having ≥3 of the
following 5 parameters: a waist circumference >102 cm for
males or >88 cm for females, serum triglyceride levels ≥150
mg/dL, serum HDL cholesterol levels <40 mg/dL for males
or <50 mg/dL for females, systolic blood pressure ≥130
mmHg or diastolic blood pressure ≥85 mmHg, and a fast-
ing blood glucose ≥110 mg/dL. Those patients with pri-
mary gout, as defined by the ACR preliminary criteria for
the classification of acute gout (8), were included in the study,
and patients with secondary gout (e.g., drug-induced or due
to chronic renal failure) were excluded. As corticosteroid thera-
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The Prevalence of Metabolic Syndrome in Patients with Gout
: A Multicenter Study
It has been suggested that hyperuricemia and possibly gout are associated with the
metabolic syndrome, but there have been no direct studies. This study was under-
taken to obtain the prevalence of the metabolic syndrome in patients with gout and
to compare it with those from the general population studies. This was a 4-institu-
tional case-historical control study composed of 168 patients with gout. We assessed
the prevalence of metabolic syndrome according to the ATP III criteria and compared
the prevalence with that of the historical controls. To elucidate the factors in gout
that were associated with metabolic syndrome, a multivariate analysis was done.
The age-adjusted prevalence of metabolic syndrome in gout patients was 43.6%,
which was significantly higher than that of the Korean control population (5.2%) from
the previous studies. Patients with gout had more components of metabolic syn-
drome than did the controls. Body mass index (BMI, OR=1.357 (95%CI 1.111-1.657))
and high density lipoprotein (HDL, OR=0.774 (95%CI 0.705-0.850)) were the vari-
ables most significantly associated with the occurrence of metabolic syndrome in
gout, but alcohol consumption did not show such associations. Gout is associated
with the metabolic syndrome, and furthermore, obesity and dyslipidemia were the
factors most associated with the syndrome in these patients. 
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py may influence metabolic factors, patients who were on
chronic steroid therapy (defined as more than a month of any
steroid dosage) were also excluded. Due to the cross-section-
al nature of this study, missing data occurred in some cases
pertaining to the classification criteria (nine cases), and these
cases were negatively coded (they were regarded as not fulfill-
ing the criteria).
The prevalence of metabolic syndrome obtained from this
study was age-adjusted with using the male population from
the year 2000 Population Projection for Korea (9). The preva-
lence of metabolic syndrome in this study was compared with
that from the previous studies done in Korea with the gen-
eral population, which prevalence was also age-adjusted by
using epidemiologic methods. Among the reports, we used
the prevalence reported by Lee et al. (10) (5.2%: male sex only,
total prevalence: 6.8%) as the prevalence of the general pop-
ulation since it was based on the largest sample size (40,698
persons). There has been a study derived from a national health
survey (11) and it reported a 22.1% prevalence among males,
but that study used the modified ATP III criteria, in which
the waist circumference criteria is adjusted to males ≥90 cm
and females ≥80 cm according to the WHO Asia-Pacific
obesity criteria (APC) (12), and so our results were compared
separately to that study. Historical controls were used for the
reason that such data would be more representative of the
general population than using clinical data from institutions
and so this should make a more objective comparison. As
hyperuricemia and hypertriglyceridemia are associated with
alcohol consumption and this may confound the results, the
amount of alcohol consumption was checked in a categorized
fashion. We classified the patients by the average daily alco-
hol consumption into three groups; non-drinkers, moderate
drinkers (≤30 g/day), or heavy drinkers (>30 g/day). 
A case-only analysis for comparing gout patients with or
without metabolic syndrome by multiple logistic regression
analysis was conducted to determine the strongest factors
associated with the occurrence of metabolic syndrome with
gout. Statistical analysis was done with SPSS for Windows
10.0 (SPSS Inc. Chicago, U.S.A.). Comparisons between the
continuous or categorical variables were done by t-tests or
chi-square tests, respectively. To compare variables among
the different alcohol consumption groups, we used one-way
analysis of variance (ANOVA). The prevalence, expressed as
rates, was compared using chi-square tests of homogeneity.
Multiple logistic regression analysis was applied for the multi-
variate analysis as described above, and the results are given
in odds ratios (OR) with 95% confidence intervals (95% CI).
Variables with pvalues of <0.05 were considered significant.
RESULTS
Descriptive analysis 
A total of 168 patients with gout were recruited from the
four hospitals. Table 1 shows the descriptive data of these
patients. All the patients were males, and the mean age was
53±11.9 yr. Almost half (47.6%) were hypertensive and
10.7% were diabetic, and this is similar to previous data from
patients with gout (13). Forty-two percent (42.9%) drank
in moderation (≤30 g/day) and 28.6% drank heavily (>30
g/day) (Table 2). Differences in the variables among the alco-
hol consumption groups could be seen for the triglyceride
and glucose levels. The triglyceride levels increased linearly
in proportion to the alcohol consumption levels, while the
glucose levels were lowest among the moderate drinkers. The
urate levels were not significantly different among the groups
(Table 2).
Prevalence of the metabolic syndrome in patients with gout
The age-adjusted prevalence of metabolic syndrome with
gout was 43.6%, which is significantly higher than that of
the control population (10) (p<0.001) (Table 3). When using
the modified ATP III criteria where the waist criteria is lowered
to ≥90 cm in males and ≥80 cm in females, the prevalence
jumped up to 57.2%, and this is also significantly higher
Factors Mean±Standard deviation
Age (yr) 53.0±11.9
Height (cm) 168.6±5.3
Weight (kg) 74.0±10.3
Body mass index (BMI, kg/m
2) 25.97±2.96
Waist (cm) 92.8±7.8
Systolic blood pressure (SBP, mmHg)   132.7±17.9
Diastolic blood pressure (DBP, mmHg) 83.9±11.1
Fasting blood glucose (FBS, mg/dL) 102.9±22.7
Total cholesterol (mg/dL) 201.6±43.6
Triglyceride (TG, mg/dL) 230.3±202.8
HDL (mg/dL) 45.2±10.8
LDL (mg/dL) 115.7±35.6
Serum uric acid (mg/dL) 7.3±2.4
Serum creatinine (mg/dL) 1.2±0.29
Hypertension 47.6%
Diabetes 10.7%
Table 1. Descriptive data of the patients with gout 
Average daily alcohol consumption
Non-drinker > 30 g/day
p
≤30 g/day
Prevalence of MS* 19 (11.3%) 26 (15.5%) 18 (10.7%) 0.929
�
FBS (mg/dL)
�
109.1±26.7
‖ 98.4±17.7
‖ 103.9±24.0 0.04
�
TG (mg/dL)
�
175.1±97.7
¶ 234.3±161.5 279.6±302.7
¶ 0.04
�
Uric acid (mg/dL)
�
7.8±2.2 6.9±2.4 7.4±2.6 0.97
�
Total 48 (28.6%) 72 (42.9%) 48 (28.6%) -
Table 2. Metabolic factors according to alcohol consumption
*Metabolic syndrome, 
� chi-square test of homogeneity, 
� One-way ANOVA,
�Mean±SD, ‖p=0.036, 
¶p=0.034, Bonferroni test.
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than that of the control population (11). According to these
results, gout is strongly associated with the metabolic syn-
drome. The prevalence of metabolic syndrome according to
the age groups is shown in Table 4. The prevalence is nearly
uniform (50-60%) across the age groups when using the modi-
fied ATP III criteria. The percentage of patients who fulfilled
the individual components of the ATP III or modified ATP
III criteria is shown in Table 5. Among the components, hyper-
tension and hypertriglyceridemia were the most common
components, and this is similar to both the control popula-
tions. Table 6 shows the percentage of patients who simulta-
neously fulfilled several components of each set of criteria in
an incremental order. Seventy-two percent of the patients with
gout had at least 2 components of metabolic syndrome (85.7%
with the modified ATP III criteria), which is much higher
than the values of 23.2% (ATP III) (10) or 46.4% (modified
ATP III) (11) from the control populations. 
Factors associated with the metabolic syndrome in patients
with gout 
The multivariate analysis displayed on Table 7 shows the
independent variables associated with the occurrence of meta-
bolic syndrome (ATP III criteria) with gout. The patients
with higher body mass index (BMI) levels were at the great-
est risk of having metabolic syndrome (OR 1.357, 95%CI
1.111-1.657, p= 0.003), while the patients with higher high
density lipoprotein (HDL) levels were at the lowest risk (OR
0.774, 95% CI 0.705-0.850, p<0.001). When considering
the difference in the weights of the units among the variables,
(i.e., increasing BMI by 1 is far more difficult than increas-
ing blood pressure or glucose by 1), systolic blood pressure
(SBP) could be the strongest variable with an OR of 2.203
(increments in 10 mmHg). However, neither the urate levels
nor the alcohol consumption levels were significantly asso-
ciated with metabolic syndrome. 
DISCUSSION
The concept of metabolic syndrome was first suggested by
Reaven in 1988 (14), and it is now an acknowledged major
risk factor for cardiovascular diseases in the ATP III guide-
lines. Its components can be divided into hypertension, obe-
sity, hyperglycemia and dyslipidemia. As gout is also gener-
ally known to be associated with such metabolic abnormali-
ties, it seems somewhat unusual that there have not been few,
if not any, epidemiologic studies concerning the prevalence
of metabolic syndrome in patients with gout up to this time.
This study is the first in Korea to determine the association
of metabolic syndrome with gout by performing a prevalence
comparison with using the ATP III classification criteria. There
Criteria Gout patients Control group p*
ATP III 63 (37.5/43.6%)
�
5.2%
�
<0.001
Modified ATP III 98 (58.3/57.2%)
�
22.1%
�
<0.001
Table 3. The prevalence of metabolic syndrome 
*Chi-square test of homogeneity, 
� crude/age-adjusted prevalence, 
� From
reference 10, study population 40,698, 
�From reference 11, study popula-
tion 6,147.
Age (yr) Prevalence (ATP III) Modified ATP III
20-29 3 (60.0%) 3 (60.0%)
30-39 7 (41.2%) 9 (52.9%)
40-49 15 (31.3%) 25 (52.1%)
50-59 19 (45.2%) 29 (69.0%)
60-69 14 (35.9%) 22 (56.4%)
70-79 5 (29.4%) 10 (58.8%)
Total 63 /168 (37.5/43.6%)* 98 /168 (58.3/57.2%)*
Table 4. Prevalence of metabolic syndrome according to age
groups
*Crude/Age-adjusted prevalence.  Criteria Percentage
Waist (ATP III) 11.9%
Waist (Modified ATP III) 66.1%
Triglyceride 66.7%
HDL 35.1%
Blood pressure 72.0%
Glucose 28.6%
Table 5. Fulfillment of the individual criteria for patients with gout
No. of criteria Percentage (ATP III) Modified ATP III
≥1 94.0% 95.8%
≥2 72.0% 85.7%
≥3 37.5% 58.3%
≥4 10.1% 24.4%
5 0.6% 4.2%
Table 6. Simultaneous fulfillment of metabolic criteria for patients
with gout 
Factor OR (95% CI) p
Age (yr) 1.002 (0.947-1.061) 0.932
BMI 1.357 (1.111-1.657) 0.003
Systolic BP 1.082 (1.029-1.139) 0.002
Diastolic BP 1.019 (0.943-1.100) 0.641
FBS 1.070 (1.037-1.105) <0.001
Triglycerides 1.005 (1.002-1.009) 0.002
HDL 0.774 (0.705-0.850) <0.001
LDL 1.014 (0.997-1.032) 0.110
Urate 0.869 (0.682-1.107) 0.256
Alcohol (Non) 1.000 0.607
≤30 g/day 0.806 (0.199-3.269) 0.763
>30 g/day 1.589 (0.355-7.106) 0.545
Table 7. Multivariate analysis of the metabolic factors for patients
with gout 
OR, Odds ratio; CI, Confidence interval; BMI, Body mass index; BP, Blood
pressure; FBS, Fasting blood glucose. ATP III Criteria were used. 1032 Y.H. Rho, S.J. Choi, Y.H. Lee, et al.
is an article reporting that 86% of patients with gout have
metabolic syndrome (15). As discussed in this report, this
difference in prevalence may reflect a difference between
diverse ethnic populations. Our results were remarkably sim-
ilar to the results of that of the single-center study (7), and
they suggest that gout is associated with metabolic syn-
drome as there is a much higher prevalence of metabolic
syndrome in patients with gout than in the general popula-
tion. This is true even when comparing with a study from a
middle-aged Korean population (17.6%) (16), which age
distribution may match the gout-prevalent ages. The major-
ity of patients with gout (>70%) had at least two metabolic
risk factors, suggesting that these patients may have a higher
risk for cardiovascular complications than normal individuals.
Obesity (or hypertension) may have stronger effects on the
development of metabolic syndrome in gout than the other
components. However, the urate levels, and more importantly,
alcohol consumption did not have significant effects on the
occurrence of metabolic syndrome in patients with gout. This
has significance in terms of the effects of alcohol on the lipid
levels. Alcohol consumption has been recently confirmed to
have an effect on the development of gout (17). Also, such
alcohol consumption could lead to higher triglyceride levels
and lower HDL levels, which may lead to an increased preva-
lence of metabolic syndrome. However, this was not the case
in our study. Because the prevalence of metabolic syndrome
did not differ across the levels of alcohol consumption, and
also because the triglyceride and HDL variables, even when
they were adjusted for alcohol consumption, remained sig-
nificant on the multivariate analysis, the effects of alcohol
on metabolic syndrome in patients with gout does not seem
to be significant. As the effects of alcohol consumption on
the development of metabolic syndrome or insulin resistance
are not consistent, as was shown in previous studies (18-22),
interpretation of our results should be done cautiously. We
give the meanings that alcohol consumption did not influ-
ence metabolic factors such as lipid levels to make more cases
of the metabolic syndrome, and so did not confound us that
gout has more individuals with metabolic syndrome through
alcohol consumption. Although gout seems to be associated
with metabolic syndrome due to its higher prevalence, serum
urate did not play a significant role in the development of
metabolic syndrome in our patients. This might have hap-
pened due to the fact that many of the patients should have
been on hypouricemic therapy, and more importantly, since
virtually all patients with gout are hyperuricemic, it may be
expected to have made no differences. However, uric acid
was included in the model for the purpose of controlling for
possible confounding, and the results are the same without
the urate variable. Therefore, a more generalized case-control
study might indicate the significance of uric acid in metabolic
syndrome. There is a study that uric acid is related to the
components of the metabolic syndrome in the Korean pop-
ulation. (23) 
This study might have some weakness, as there were 7
cases (4.2%) missing from the waist data and 2 cases (1.2%)
missing from the blood pressure data. However, as the miss-
ing values were negatively coded, these should not have had
an influence on our conclusions. The significance of obesity
and HDL as the strongest positive and negative factors for
metabolic syndrome in gout patients should be revalidated
and if it is so, this may give insights into the development
of hyperuricemia and gout and hopefully, lead to its effective
management. Obesity, as well as low HDL levels combined
with hypertriglyceridemia are suggested to be associated with
insulin resistance (24-26), and as they were the variables with
the strongest effects on metabolic syndrome in patients with
gout, our data indicates that gout (or hyperuricemia) is more
related with dyslipidemia and obesity rather that hypergly-
cemia or hypertension. As patients with gout are essentially
a subgroup of hyperuricemic individuals, larger samples are
needed to generalize to, or to compare with the asymptomatic
hyperuricemic individuals, who in fact represent the major-
ity of the hyperuricemic population. The results from such
studies may give more perspectives on the development of
hyperuricemia. 
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